A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. [electronic resource]
Producer: 20060404Description: 7807-16 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Area Under Curve
- Depsipeptides -- administration & dosage
- Dose-Response Relationship, Drug
- Female
- Humans
- Infusions, Intravenous
- Male
- Maximum Tolerated Dose
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Metastasis
- Neoplasms -- drug therapy
- Oligopeptides -- administration & dosage
- Time Factors
- Tomography, X-Ray Computed
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.